Evidence map›Paper›PMID 28542202›Full record

ArticlePLoS neglected tropical diseases2017

Unravelling the rate of action of hits in the Leishmania donovani box using standard drugs amphotericin B and miltefosine.

Diana Tegazzini, Juan Cantizani, Imanol Peña, Julio Martín, Jose M Coterón

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Diana TegazziniKinetoplastids DPU, Diseases of the Developing World (DDW), GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Juan CantizaniKinetoplastids DPU, Diseases of the Developing World (DDW), GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Imanol PeñaKinetoplastids DPU, Diseases of the Developing World (DDW), GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Julio MartínKinetoplastids DPU, Diseases of the Developing World (DDW), GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Jose M CoterónKinetoplastids DPU, Diseases of the Developing World (DDW), GlaxoSmithKline, Tres Cantos, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the neglected diseases drug discovery community has elected phenotypic screening as the key approach for the identification of novel hit compounds. However, when this approach is applied, important questions related to the mode of action for these compounds remain unanswered. One of such questions is related to the rate of action, a useful piece of information when facing the challenge of prioritising the most promising hit compounds. In the present work, compounds of the "Leishmania donovani box" were evaluated using a rate of action assay adapted from a replicative intracellular high content assay recently developed. The potency of each compound was determined every 24 hours up to 96 hours, and standard drugs amphotericin B and miltefosine were used as references to group these compounds according to their rate of action. Independently of this biological assessment, compounds were also clustered according to their minimal chemical scaffold. Comparison of the results showed a complete correlation between the chemical scaffold and the biological group for the vast majority of compounds, demonstrating how the assay was able to bring information on the rate of action for each chemical series, a property directly linked to the mode of action. Overall, the assay here described permitted us to evaluate the rate of action of the "Leishmania donovani box" using two of the currently available drugs as references and, also, to propose a number of fast-acting chemical scaffolds present in the box as starting points for future drug discovery projects to the wider scientific community. The results here presented validate the use of this assay for the determination of the rate of action early in the discovery process, to assist in the prioritisation of hit compounds.

Indexed as

Amphotericin BAntiprotozoal AgentsCell Line, TumorDrug Evaluation, PreclinicalHumansLeishmania donovaniLeishmaniasis, VisceralMacrophagesPhosphorylcholineAmphotericin BAntiprotozoal AgentsmiltefosinePhosphorylcholine

Identifiers

PMID28542202
PMCPMC5462473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.